Mesothelioma - The `Orphan` Cancer
Released on: October 10, 2007, 12:30 am
Press Release Author: The Law Offices of James Sokolove
Industry: Law
Press Release Summary: Government funding remains elusive for deadly disease
Press Release Body: While Americans have long been romanced by campaigns for breast cancer and leukemia research, it may be some time before mesothelioma enjoys a stint in the spotlight. Despite the fact that over 2,500 cases of the disease are diagnosed in the U.S. each year-with as many or more dying from it-the need to develop effective treatments for mesothelioma victims continues to be overlooked by the federal government.
"Even though it has been medically documented since the 1940s, mesothelioma remains very much an 'orphan' disease today," says Attorney Jim Sokolove, principal and founder of the Law Offices of James Sokolove (www.jimsokolove.com). "The government has yet to recognize this disease as the epidemic that it really is." Between 2000 and 2003, the National Cancer Institute (NCI) invested less than $2 million annually in clinical research for mesothelioma-a fraction of the funds invested in other types of cancers. And although Congress has allocated $3.75 billion for research on various diseases since 1992, none of this money has been allocated to furthering mesothelioma studies. With no effective treatments available, the disease is almost always fatal, with an average survival time of 12 months following diagnosis. Sokolove cites complex economic and political factors among the many reasons why mesothelioma has failed to receive significant national funding. \"Although enormous financial resources are available to help improve mesothelioma treatment, there is no real effort to commit these resources."
One group is lobbying aggressively to reverse the rising tide of mesothelioma deaths in the U.S. The Mesothelioma Applied Research Foundation (MARF) coordinates numerous efforts to advance funding, studies and treatment for the disease. In 2005, MARF succeeded in obtaining from Congress the first appropriation ever for mesothelioma research.
The Law Offices of James Sokolove worked closely with MARF in the development of its new website, the Mesothelioma Resource Center (www.mesorc.com), a comprehensive support and information resource for mesothelioma victims and their families.
"MARF is doing extraordinary things in getting the voice of the mesothelioma community to be heard," Sokolove remarks. "Through the Mesothelioma Resource Center, the LOJS hopes to compliment their efforts and provide much-needed support to victims and their loved ones."
Those interested in learning more about mesothelioma research, clinical trials, and treatments can register for free updates at www.mesorc.com. For each person that signs up, the Law Offices of James Sokolove will make a $200 donation to MARF.
About The Law Offices of James Sokolove The Law Offices of James Sokolove (LOJS) is the nation's largest and fastest growing marketer of legal services, providing qualified law firms, with the most cost efficient and highly qualified case leads. For over 30 years, the LOJS has endeavored to reinvent how people obtain legal services, in order to provide everyone, irrespective of ethnicity or income, equal access to our civil justice system and within it, superior quality of representation and service. Working with an affiliate network of over 300 law firm throughout the US, the LOJS generates over 200,000 leads and 12,000 signed cases annually, translating into over one quarter billion in revenue dollars for its affiliates. As the legal profession continues to experience unprecedented and dynamic change, the LOJS business model is a proven success as it strategically matches specific client needs with particular law firm expertise.
Web Site: http://
Contact Details: The Law Offices of James Sokolove, 1340 Centre St # 102, Newton Center, Massachusetts MA 02459
Martin Lock Phone: 617-742-0696 Ext 413 Fax: 617-964-4336 Email: mlock@jimsokolove.com URL: www.jimsokolove.com
Printer
Friendly Format
Back
to previous page...
Back
to home page...
Submit
your press releases...
|